Yes, this is the second time that there's been an advance market commitment, an AMC, that's been created for a new vaccine. The first one was for the pneumococcal conjugate vaccine, and that was created about a decade ago.
The basic idea is that we pool funds together, and it demonstrates that there is a viable financial market that would allow manufacturers to scale up production because they know that there's going to be somebody who's going to purchase it on the other end.
The devil is in the details with all of these things. Going back to the pneumonia vaccine AMC, it lacked a clear mechanism for humanitarian organizations to be able to access the vaccine for populations that fall outside of the Gavi distribution and the typical health systems access mechanisms. We spent many years fighting for a humanitarian mechanism to gain access at an affordable price.
I think this is clearly a positive development, where we see the development of COVAX and the AMC coming together. These are positive steps, let's be clear about that, but it's also important that we get the details right to make sure that access is going to be ensured at an affordable price for everyone.